...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Gynecological endocrinology: the official journal of the International Society of Gynecological Endocrinology >Coagulation and fibrynolitic parameters in women and the effects of hormone therapy; Comparison of transdermal and oral administration
【24h】

Coagulation and fibrynolitic parameters in women and the effects of hormone therapy; Comparison of transdermal and oral administration

机译：妇女的凝血和纤溶参数以及激素治疗的影响;透皮和口服给药的比较

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

It is established that hormone therapy (HT) is related with significant increased prothrombotic risk factor. The aim of our study was to assess the effects of oral hormone therapy (o-HT) and transdermal hormone therapy (t-HT) on hemostasis parameters: fibrinogen (Fg) concentration, the maximum velocity of polymerization of clot formation, fibrin half-time lysis, plasma level of thrombin inhibitor of fibrinolysis (TAFI) and activity of generated thrombin and plasmin amidolytic activity. We observed that values of initial velocity of polymerization in o-HT group were increased (94.64 mOD/min vs. 131.50 mOD/min, p < 0.001) compared to control group. Fibrin lysis half-time increased in both groups with HT (controls-18.26min vs. 32.43min (o-HT); 23.34min transdermal hormone therapy (t-HT) p < 0.001) compared to controls. The activity of thrombin was statistically higher in plasma of women after o-HT (72.6??8.5 mOD/min) than in patients with t-HT (53.7??10.1 mOD/min) and controls (51.2??10 mOD/min. Plasmin activity was the highest in controls (84.5??10.2 mOD/min). The highest level of TAFI we observed in patients after oral hormones (80.38??8.23%); women on transdermal HT had 61.58??9.81% and the lowest concentration of TAFI we noted in controls 44.70??10.16). The results of our study show that HT may partly explain the increase in venous thrombosis (VTE) and cardiovascular events reported after the use of it, especially the oral form of treatment. ? 2013 Informa UK, Ltd.
机译：已确定激素治疗（HT）与血栓形成前危险因素显着增加有关。我们研究的目的是评估口服激素治疗（o-HT）和透皮激素治疗（t-HT）对止血参数的影响：纤维蛋白原（Fg）浓度，血凝块形成的最大聚合速度，溶血时间，凝血酶纤溶酶抑制剂（TAFI）的血浆水平，产生的凝血酶活性和纤溶酶酰胺分解活性。我们观察到，与对照组相比，o-HT组的初始聚合速度值增加了（94.64 mOD / min对131.50 mOD / min，p <0.001）。与对照组相比，两组中纤维蛋白溶解的半衰期延长（对照组：18.​​26min vs. 32.43min（o-HT）; 23.34min透皮激素治疗（t-HT）p <0.001）。经统计学分析，o-HT后妇女血浆中的凝血酶活性（72.6 ?? 8.5 mOD / min）高于t-HT患者（53.7 ?? 10.1 mOD / min）和对照组（51.2 ?? 10 mOD / min）。对照组中血浆蛋白活性最高（84.5 ?? 10.2 mOD / min），口服激素后患者的TAFI水平最高（80.38 ?? 8.23％）;经皮HT的女性为61.58％9.81％，我们在对照中注意到TAFI的最低浓度为44.70-10.16）。我们的研究结果表明，HT可能部分解释了使用HT后静脉血栓形成（VTE）和心血管事件的增加，尤其是口服治疗。 ？ 2013 Informa UK，Ltd.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号